Seres Therapeutics Inc (MCRB) — Titan Protect Analysis

MCRB

Seres Therapeutics Inc

Healthcare · ·

$6.63

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$73M

Total market value of the company

Trailing P/E

N/A

Forward P/E

-0.74

Based on estimated future earnings — lower means cheaper

Rev Growth

N/A

Year-over-year revenue change

Profit Margin

N/A

How much profit the company keeps from each dollar of revenue

ROE

-121.9%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$22.00

+232% from current price — median analyst estimate

Recommendation

NONE

Consensus view from 1 analysts covering this stock

About Seres Therapeutics Inc

Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize GI pathogens, enhance GI epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation. It also develops SER-603, a LBP

https://www.serestherapeutics.com

Country: United States Employees: 66 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKDOWN

Price trending down — defensive positioning

Sharpe Ratio

0.013

Positive but modest risk-adjusted returns

Kelly Fraction

-0.0167

No positive edge detected — the data suggests staying out

Calmar Ratio

-0.588

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-45.4%

Historical annualised return based on price data

Max Drawdown

-77.1%

Largest peak-to-trough decline — the worst it has been

HMM State

BEAR

Statistical model detects bearish conditions

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

0.12

Very low correlation to market moves

52W High

$29.98

78% below the year high

52W Low

$6.56

1% above the year low

Avg Volume

46,474

Average daily shares traded — higher means easier to buy and sell

Short Ratio

9.5

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-5.20

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

303.78

Heavy leverage — higher financial risk if revenues decline

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

N/A

Revenue left after cost of goods — higher means pricing power

Operating Margin

-5,839.9%

Profit from core operations before interest and tax

Free Cash Flow

$-41,538,248

Negative — the business is spending more than it generates

Revenue (TTM)

$1M

Total revenue over the last 12 months

Net Income

$-46,899,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$22.00

Target Median

$22.00

Target Low

$22.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go